Royalty In 'Wait-And-See' Mode With $6.3B Elan Tender Offer
Royalty Pharma Inc. on Thursday extended a hostile tender offer valuing pharmaceutical company Elan Corp. PLC at $6.3 billion, taking a wait-and-see approach to Elan's upcoming shareholder meeting and an injunction...To view the full article, register now.
Already a subscriber? Click here to view full article